The Clinical Trial Vanguard

What are Pragmatic Trials?

The Clinical Trial Vanguard — Wed, 05 Mar 2025 10:50:51 +0000

Pragmatic trials are a transformative approach in clinical research designed to integrate real-world data into clinical trials. They aim to bridge the gap between clinical research and practice by ensuring that trial results are applicable to broader, real-world populations. Here are some key aspects of pragmatic trials: Real-world applicability: Pragmatic trials are designed to determine whether a therapy works in diverse, real-world settings, addressing a question often unanswered by traditional randomized controlled trials (RCTs) due to their controlled nature and homogeneous populations. Flexibility: Pragmatic trials offer flexibility by allowing the integration of existing data and the enrollment of diverse populations...

The post What are Pragmatic Trials? first appeared on The Clinical Trial Vanguard.

Key Takeaways from SCOPE Summit 2025: Budget Negotiations, Protocol Design, and AI in Clinical TrialsSCOPE Summit Summary

The Clinical Trial Vanguard — Sat, 01 Mar 2025 20:54:02 +0000

The SCOPE Summit 2025 addressed key areas in clinical trials: budget negotiations, protocol design, and AI integration. Clinical Trial Budget Negotiations: The summit addressed unresponsive sites and budget discrepancies3. It promoted clear communication, thorough feasibility assessments, and flexible fair market value (FMV) parameters to improve negotiation efficiency and fairness. Enhancing Clinical Trial Protocol Design: Collaboration between Mass General Brigham (MGB), AstraZeneca, and Evinova focuses on improving communication, data utilization, and patient-centric approaches MGB’s HERO initiative and AstraZeneca’s patient partnership program were highlighted as ways to enhance study feasibility, patient engagement, and recruitment. AI Integration: The summit emphasized the transformative role...

The post Key Takeaways from SCOPE Summit 2025: Budget Negotiations, Protocol Design, and AI in Clinical TrialsSCOPE Summit Summary first appeared on The Clinical Trial Vanguard.

FDA’s Diversity in Clinical Trials Plan: Why It Fails to Address Key Barriers for Underrepresented Communities

The Clinical Trial Vanguard — Mon, 23 Sep 2024 13:12:44 +0000

This is an AI-Generated podcast. This podcast discusses the FDA’s recent guidance on inclusion and diversity in clinical trials and features an interview with Mumbi Kairu, a nurse practitioner at the Pamoja Research Institute. Kairu discusses the crucial need for diversity in clinical trials, noting that while the FDA guidance is a step in the right direction, it does not adequately address the cultural and socioeconomic barriers that prevent diverse participation. Kairu argues that building community trust should be paramount, as historical events like the Tuskegee experiment still generate mistrust. She suggests involving more community physicians and clinics could help...

The post FDA’s Diversity in Clinical Trials Plan: Why It Fails to Address Key Barriers for Underrepresented Communities first appeared on The Clinical Trial Vanguard.